Trial Profile
A Clinical Trial to Validate Molecular Targets of Vorinostat in Patients With Aerodigestive Tract Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Vorinostat (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Pharmacodynamics
- 08 Oct 2018 Status changed from active, no longer recruiting to completed.
- 02 Dec 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 28 Oct 2011 Planned end date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.